Rockefeller Capital Management L.P. Buys 76,727 Shares of ACADIA Pharmaceuticals Inc. $ACAD

Rockefeller Capital Management L.P. boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 7.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,113,040 shares of the biopharmaceutical company’s stock after purchasing an additional 76,727 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in ACADIA Pharmaceuticals were worth $29,729,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ACAD. Farther Finance Advisors LLC increased its holdings in ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 386 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $26,000. Transamerica Financial Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 304.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 1,005 shares in the last quarter. Federated Hermes Inc. increased its stake in ACADIA Pharmaceuticals by 277.5% in the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,185 shares during the last quarter. Finally, Leonteq Securities AG bought a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $52,000. Institutional investors own 96.71% of the company’s stock.

Analyst Ratings Changes

ACAD has been the subject of several recent analyst reports. Royal Bank Of Canada cut their target price on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Mizuho upgraded ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $29.00 to $35.00 in a research note on Monday, February 23rd. Wolfe Research started coverage on ACADIA Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $33.00 price target for the company. Weiss Ratings downgraded ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. raised their price objective on ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Wednesday, March 4th. Eleven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $31.62.

Insider Buying and Selling

In related news, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the sale, the insider directly owned 24,509 shares in the company, valued at $519,100.62. This trade represents a 18.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $76,395.74. Following the sale, the executive vice president directly owned 66,145 shares in the company, valued at $1,441,299.55. The trade was a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 13,978 shares of company stock valued at $302,819. 26.20% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Trading Up 2.2%

ACADIA Pharmaceuticals stock opened at $22.09 on Tuesday. The company has a market capitalization of $3.78 billion, a PE ratio of 10.04, a P/E/G ratio of 27.14 and a beta of 0.84. ACADIA Pharmaceuticals Inc. has a 12 month low of $19.69 and a 12 month high of $28.35. The stock has a 50-day moving average price of $21.66 and a two-hundred day moving average price of $23.52.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $268.10 million for the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.11 earnings per share. As a group, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current fiscal year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.